Cell Survival Assays for Individualised Chemotherapy in Primary Glioma Cultures—Colourmetric or Luminescent英文文献资料.docVIP

Neuroscience Medicine, 2011, 2, 376-383 doi:10.4236/nm.2011.24050 Published Online December 2011 (http://www.SciRP.org/journal/nm) Cell Survival Assays for Individualised Chemotherapy in Primary Glioma Cultures— Colourmetric or Luminescent? Timothy P. Dawson , Katherine Ashton, Aprajay Golash , Charles H. G. Davis , R. Venkat Iyer , 1* 1 1 2 3 3 Phil Roberts 3 , Fred Harris , Robert W. Lea 1 2 3 Lancashire Teaching Hospitals NHS Trust, Preston, UK; Frenchay Hospital, Frenchay, Bristol, UK; University of Central Lanca- shire, Preston, UK. * E-mail: Timothy.Dawson@lthtr.nhs.uk Received October 13 , 2011; revised November 18 , 2011; accepted November 26 , 2011. th th th ABSTRACT In vitro chemosensitivity testing of short term primary glioma cultures derived from brain biopsies is still in the re- search phase and has not yet found a place in clinical use. The main reasons for this slow progression are the small amounts of tissue available and the lack of a suitably sensitive assay capable of use in the clinical setting. This study examines whether the MTS and ATP cell survival assays, which determine cytotoxicity via colorimetric and lumines- cence analysis respectively, could potentially fulfill this role. Primary glioma cultures were tested for chemosensitivity using the MTS and ATP assays and were found to be generally sensitive to cisplatin and paclitaxel but relatively resis- tant to carmustine and etoposide. For both assays, LD50 values lay i